Kestra Medical Technologies (NASDAQ:KMTS) Sets New 1-Year Low - Time to Sell?

Shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) reached a new 52-week low on Wednesday . The company traded as low as $14.45 and last traded at $15.07, with a volume of 383439 shares. The stock had previously closed at $16.65.

Analyst Upgrades and Downgrades

KMTS has been the subject of a number of recent research reports. The Goldman Sachs Group dropped their target price on Kestra Medical Technologies from $24.00 to $23.00 and set a "neutral" rating for the company in a research report on Wednesday, April 16th. Piper Sandler started coverage on Kestra Medical Technologies in a report on Monday, March 31st. They issued an "overweight" rating and a $27.00 price objective for the company. Wolfe Research started coverage on Kestra Medical Technologies in a report on Monday, March 31st. They issued an "outperform" rating and a $29.00 price objective for the company. Bank of America started coverage on Kestra Medical Technologies in a report on Monday, March 31st. They issued a "buy" rating and a $30.00 price objective for the company. Finally, Stifel Nicolaus started coverage on Kestra Medical Technologies in a report on Monday, March 31st. They issued a "buy" rating and a $28.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $27.50.

Kestra Medical Technologies Price Performance

The stock has a 50-day simple moving average of $22.14.

Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last issued its earnings results on Monday, April 14th. The company reported ($1.25) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.61). During the same quarter in the prior year, the business posted ($1.18) earnings per share.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in KMTS. Eventide Asset Management LLC bought a new position in shares of Kestra Medical Technologies during the 1st quarter valued at about $6,853,000. Russell Investments Group Ltd. bought a new position in shares of Kestra Medical Technologies during the 1st quarter valued at about $457,000. Armistice Capital LLC bought a new position in shares of Kestra Medical Technologies during the 1st quarter valued at about $312,000. Ghisallo Capital Management LLC bought a new position in shares of Kestra Medical Technologies during the 1st quarter valued at about $1,869,000. Finally, Omega Fund Management LLC bought a new position in shares of Kestra Medical Technologies during the 1st quarter valued at about $44,754,000.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.